[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]

Incentives and Disincentives for Vaccine Development: A Biotech Perspective Safety * Safety parameters must be determined, with risk/benefit taken into consideration before large scale clinical trials of a preventive vaccine are begun. * A whole gpl20 depleted inactivated virus vaccine has been injected into over 1,000 HIV seropositives with no serious treatment related adverse events. Page 5

/ 37

Actions

file_download Download Options Download this page PDF - Pages 1- Image - Page 5 Plain Text - Page 5

About this Item

Title
[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]
Author
Weniger, Bruce
Canvas
Page 5
Publication
1997-01-10
Subject terms
memorandums
Item type:
memorandums

Technical Details

Link to this Item
https://name.umdl.umich.edu/5571095.0495.212
Link to this scan
https://quod.lib.umich.edu/c/cohenaids/5571095.0495.212/10

Rights and Permissions

The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.

Manifest
https://quod.lib.umich.edu/cgi/t/text/api/manifest/cohenaids:5571095.0495.212

Cite this Item

Full citation
"[Memorandum to Presidential Advisory Council on HIV and AIDS Research Committee Members from Bruce G. Weniger]." In the digital collection Jon Cohen AIDS Research Collection. https://name.umdl.umich.edu/5571095.0495.212. University of Michigan Library Digital Collections. Accessed June 11, 2025.
Do you have questions about this content? Need to report a problem? Please contact us.

Downloading...

Download PDF Cancel